Risankizumab (Skyrizi) prior authorization at Blue Cross NC
Submission criteria, P2P prep, and appeal path if denied — for prescribers and PA staff
Blue Cross NC requires prior-authorization documentation for Risankizumab (Skyrizi): a diagnosis with ICD-10 code, documented step-therapy history, and prescriber attestation of medical necessity. Standard PA decisions return in 30 days; if denied, prescribers and members have 180 days to appeal.
The PA criteria you'll need to meet
Blue Cross NC reviews Risankizumab (Skyrizi) prior authorizations against its medical policy . Blue Cross NC-specific context: BCBS licensee for North Carolina (~4.3M members). Prime Therapeutics PBM. NC DOI oversight. Blue Premier is the high-profile value-based care program. Recently divested some Medicaid business; Healthy Blue (joint venture with Elevance) handles NC Medicaid.
Documentation packet checklist
- Chart note with diagnosis (ICD-10 code) and clinical severity markers
- Documented failure of, contraindication to, or intolerance of step-therapy alternatives in this class
- Prior treatment history including dosing, duration, and reason for discontinuation
- Relevant labs, imaging, or assessment scores supporting medical necessity
- Prescriber attestation linking the FDA-approved indication to the patient's presentation
- Blue Cross NC's medical policy URL referenced in the cover letter
Blue Cross NC's common denial patterns
Pre-empting these patterns in the initial submission cuts rework and shortens time-to-approval:
- Step therapy via Prime Therapeutics
- Blue Premier value-based arrangement disputes
- Out-of-network reductions
- Specialty drug PA
Risankizumab (Skyrizi)-specific denial patterns and context
Across payers (not just Blue Cross NC), Risankizumab (Skyrizi)draws a distinct set of denial reasons rooted in the drug's label, REMS, and competitive landscape:
- Step therapy requiring TNF and/or ustekinumab first
- Crohn's indication denial despite FDA approval (2022)
- UC indication denial despite FDA approval (2024)
- Specialty pharmacy network restriction
Brand: Skyrizi. IL-23 inhibitor approved for plaque psoriasis, PsA, Crohn's disease (2022), and ulcerative colitis (June 2024). AbbVie's heir-apparent post-Humira.
Manufacturer patient-assistance program: AbbVie Complete — relevant when a Blue Cross NC denial sticks and the patient needs bridge access while appealing.
How Blue Cross NC approaches Biologic drugs (mAbs and biosimilars) PAs
Blue Cross NC's Biologic drugs (mAbs and biosimilars) reviewer typically anchors Risankizumab prior-auth decisions on step therapy via prime therapeutics and specialty drug pa. Pharmacy-benefit review for Risankizumab at Blue Cross NC is routed through Prime Therapeutics. The 30-day standard review window starts when the prior-authorization request is received with all required documentation — incomplete packets pause the clock and add 5-10 days to time-to-approval, after which the 180-day internal-appeal window begins from the denial date. Blue Cross NC's utilization-management vendor (Carelon, eviCore, OptumRx, or in-house) sets the step-therapy ladder — appeals that cite ACR, AAD, or AGA guideline language directly to the medical director shorten escalation. Blue Cross NC is domiciled in NC, so unresolved appeals escalate to the NC insurance department's external-review program for fully-insured policies (self-funded ERISA plans route to the DOL EBSA instead). BCBS licensee for North Carolina (~4.
If the PA is denied
Blue Cross NC gives prescribers and members 180 days to file an internal appeal. Standard appeal decisions return within 30 days. Submit through the provider portal (https://www.bluecrossnc.com/providers) with the same packet plus a peer-reviewed citation supporting Risankizumab (Skyrizi)for the patient's indication.
Helping a patient appeal the denial directly? See the consumer guide: How to appeal a Blue Cross NC denial on DenialHelp.
Contact Blue Cross NC
- Provider portal: https://www.bluecrossnc.com/providers
Frequently asked questions
What documentation does Blue Cross NC need for Risankizumab (Skyrizi) prior auth?
Blue Cross NC's typical PA packet for Risankizumab (Skyrizi): (1) chart note documenting the indication and prior-treatment failures, (2) supporting lab/imaging where indicated, (3) prescriber attestation that step-therapy alternatives were tried or contraindicated, (4) FDA-approved indication mapped to ICD-10 diagnosis.
What's the turnaround time at Blue Cross NC?
Standard Risankizumab (Skyrizi) PA decisions at Blue Cross NC: 30 days. Urgent / expedited (member's life or function at risk): 72 hours under 45 CFR §147.136.
What does Blue Cross NC most often reject Risankizumab (Skyrizi) for?
Across Blue Cross NC's book the common rejection patterns include: Step therapy via Prime Therapeutics; Blue Premier value-based arrangement disputes; Out-of-network reductions. For Risankizumab (Skyrizi) specifically, expect step-therapy challenges and indication-restriction reviews when the use is at the edge of the FDA label or off-label.
What prior failures does Blue Cross NC typically require before approving Risankizumab?
Blue Cross NC's biologics step-therapy ladder for most indications begins with a conventional DMARD (methotrexate, sulfasalazine, leflunomide) or topical/inhaled first-line, then a step-1 biologic (typically a TNF inhibitor or adalimumab biosimilar), then the requested agent. Document trial duration (≥12 weeks for most biologics), dosing reached, and reason for discontinuation (inadequate response by disease-activity score, intolerance, or contraindication). For Risankizumab, attach the specific disease-activity instrument Blue Cross NC accepts (e.g., DAS28, PASI 75, HBI, Mayo) — appeals with raw symptom narrative but no scored instrument carry higher denial rates. Pharmacy-benefit handling is routed through Prime Therapeutics. External-review escalation for Blue Cross NC fully-insured policies sits with the NC insurance department.
How do I prep for a peer-to-peer with Blue Cross NC on Risankizumab (Skyrizi)?
Lead with the FDA-approved indication and the specific clinical criteria the policy lists. Have the patient's chart open, document number, and policy URL on screen. State your name and credentials, the policy number, the indication, and the documented failures of step-therapy alternatives. Keep notes — if the P2P reviewer overturns, get the decision in writing.
Related PA criteria
Generate the Risankizumab (Skyrizi) PA packet
Open ApprovalHelp — generate a Risankizumab (Skyrizi) prior-auth packet tailored to Blue Cross NC's criteria, with prescriber attestation and step-therapy documentation pre-filled.
Get started →Contact: hello@approvalhelp.com